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The last few years have seen remarkable developments in our 
understanding of the physiology, pharmacology and genetics of 
inhibitory glycinergic synapses. In part, this has been due to the 
development of new resources such as specific antisera recognizing 
glycine receptor (GlyR) and transporter (GlyT) subtypes, but also 
the characterization of new mouse, zebrafish and bovine genetic 
models of glycinergic dysfunction. What is also evident is the high 
quality and impact of the research conducted in this field. This is 
reflected in the reviews and research articles in this Special Issue 
entitled “Glycinergic transmission: physiological, developmental 
and pathological implications”.
The study of inhibitory synaptic transmission has a long and 
illustrious history, as documented by Callister and Graham (2010). 
Key in vivo experiments on spinal glycinergic synapses conducted in 
the 1950s and 1960s helped to define key concepts in chemical neu-
rotransmission and the distinct pharmacological and electrophysi-
ological properties of what we now know to be inhibitory GlyRs 
containing the α1 and β subunits. This major adult GlyR isoform 
predominates in the spinal cord and brainstem (Baer et al., 2009) 
and has a major role the control of spinal motor reflex circuits. 
Defects in the corresponding genes, GLRA1 and GLRB, result in an 
inherited motor disorder in humans known as hyperekplexia, char-
acterized by neonatal hypertonia and an exaggerated startle reflex. 
Modern genetics techniques (Davies et al., 2010) have revealed that 
hyperekplexia is best thought of as a synaptopathy, since muta-
tions in SLC6A5 – encoding the presynaptic glycine transporter 
GlyT2 – can also cause startle disease. Other GlyR subtypes, such 
as those containing the α2, α3 and α4 subunits, may play more 
diverse biological roles in retinal circuitry (Wässle et al., 2009) 
and central inflammatory pain sensitization (Harvey et al., 2009). 
GlyR α2 and α3 subunit transcripts are also unusual in that they 
undergo both alternative splicing and cytidine to uracil RNA editing 
(C to U), resulting in a proline to leucine substitution (P185L in 
α3, P192L in α2) that confers high agonist sensitivity and phar-
macology to “edited” GlyRs (Legendre et al., 2009). GlyR transcript 
editing may promote the generation of sustained chloride con-
ductances associated with tonic inhibition and is modulated by 
brain lesions, suggesting a possible involvement with pathogenic 
processes. These “orphan” GlyR subtypes may also have key roles 
in peripheral tissues, since GlyRs have been located on sperm and 
neutrophils. However, in renal, liver and endothelial cells, where 
glycine protects from cell death, caution should be applied in 
attributing these functions to classical GlyRs and GlyTs (Van den 
Eynden et al., 2009). Certainly, not all cell types that express GlyR 
subunit mRNAs or polypeptides exhibit GlyR-mediated membrane 
conductance changes. It is also noteworthy that NMDA receptors 
composed of the NR1 and NR3 subunits lack glutamate-binding 
sites and can be activated by glycine alone. It is therefore impera-
tive to understand the synaptic location and pharmacology of this 
“excitatory” GlyR (Madry et al., 2010).
So what does the future hold for the study of glycinergic trans-
mission? Certainly, GlyRs have a far richer pharmacology than 
has been appreciated until now. The advent of high throughput 
screening techniques using anion-sensitive EYFP has enabled 
automated electrophysiology approaches to be applied in the 
search  for  new  GlyR-active  compounds  and  subtype-specific 
modulators (Gilbert et al., 2009). In addition, further study of 
spontaneous or knockout models of GlyR and GlyT dysfunction 
has the potential to reveal new roles for these synaptic proteins. 
In particular, the biological roles of the GlyR α2 and α4 subtypes 
still remain enigmatic. The embryonic/neonatal GlyR α2 subtype 
has previously been linked to roles in synaptogenesis, cell fate/
paracrine transmitter release in the developing cortex/spinal cord 
and retinal photoreceptor development. It was therefore some-
what surprising that Glra2 knockout mice did not show a clear 
behavioral phenotype. This is most likely due to the “rewiring” 
of neuronal circuits during development allowing compensatory 
mechanisms to mask certain phenotypes. For example, the loss 
of GlyR α3 in a knockout model results in both presynaptic and 
postsynaptic compensation in the spinal cord. Lamina II syn-
apses that typically express both α3β GlyRs show an elevated 
glycine release probability, with no changes in quantal content 
onto α1β GlyRs, which continue to mediate synaptic transmis-
sion. Phenotypes revealed to date in Glra3 knockout mice have 
exclusively been linked to G-protein coupled receptor pathways 
influencing PKA-mediated phosphorylation of GlyR α3. In fact, 
these were only evident because α1β GlyRs are not modulated by 
PKA phosphorylation. Whilst new knock-in models expressing 
dominant-negative mutations might overcome this issue, other 
model organisms will undoubtedly play an important role. For 
example, zebrafish have a full complement of GlyR and GlyT genes 
and are amenable to developmental and genetic analysis using 
N-ethyl-N-nitrosourea (ENU) mutagenesis, gene-traps and rapid 
targeted gene “knockdown” using antisense morpholinos (Ganser 
and Dallman 2009; Chalphin and Saha 2010; Hirata et al., 2010). 
Curiously, the gene encoding GlyR α4 is thought to be a pseudo-
gene in humans due to a stop codon in GLRA4 exon 9, causing 
a protein truncation between membrane-spanning domains M3 
and M4. However, this finding may need revisiting in the light 
of recent resequencing studies that highlight that certain genes 
on the X chromosome are intact in some individuals but con-
tain non-sense or frameshift changes in other apparently normal Harvey and Rigo  Glycinergic transmission - special issue
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control subjects. It would therefore seem that some genes that 
are apparently inert in some humans may be active in others. It 
is also certain that additional defects involving glycinergic trans-
mission remain to be identified. Not all cases of hyperekplexia 
can be explained by mutations in the genes encoding the adult 
GlyR α1β isoform or GlyT2, implying that researchers are either 
missing mutations in important gene regulatory elements, or in 
other genes involved in the formation/function of glycinergic 
synapses (Davies et al., 2010). In addition, several hyperekplexia-
like syndromes in animals remain unresolved, such as inherited 
myoclonus in Peruvian Paso horses and familial reflex myoclonus 
in labrador retrievers. Lastly, although we know much about the 
cellular transport and membrane dynamics of GlyRs (Dumoulin 
et al., 2010) – mediated in part by the multifunctional protein 
gephyrin -our knowledge concerning proteins associated with 
GlyRs and GlyTs is still painfully thin. The development of reli-
able antibodies that function in immunoprecipitation and the 
application of modern proteomics techniques to the study of 
glycinergic synapses is therefore a priority for the future.
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